InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,343.96
(
0.15%
)
Post# of 252302
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

rfj1862

Send PM Follow Ignore
Followers 39
Posts 1714
Boards Moderated 0
Alias Born 10/05/2005

rfj1862

Re: Whalatane post# 246324

Monday, 04/10/2023 2:55:09 PM

Monday, April 10, 2023 2:55:09 PM

Post# of 252302

IgaN Nephropathy trials ....2 P 3 readouts / interims I'm aware of in 2023
This is the P 2 data from OMER ...pretty impressive
https://www.businesswire.com/news/home/20211105005398/en/Omeros-Announces-Results-From-Nearly-Three-Year-Follow-up-of-Patients-in-Phase-2-IgA-Nephropathy-Trial



The problem here is that it is an IV infusion in a patient population that is already receiving significant medical treatment.

Oral trumps IV almost (but not quite) always.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up